136 related articles for article (PubMed ID: 19743897)
1. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
Papeo G; Forte B; Orsini P; Perrera C; Posteri H; Scolaro A; Montagnoli A
Expert Opin Ther Pat; 2009 Oct; 19(10):1377-400. PubMed ID: 19743897
[TBL] [Abstract][Full Text] [Related]
2. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitors in cancer therapy: an update.
Papeo G; Casale E; Montagnoli A; Cirla A
Expert Opin Ther Pat; 2013 Apr; 23(4):503-14. PubMed ID: 23379721
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Horvath EM; Szabó C
Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of poly(ADP-ribose) polymerase in cancer.
Plummer ER
Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
[TBL] [Abstract][Full Text] [Related]
6. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
Lewis C; Low JA
Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule PARP modulators--current status and future therapeutic potential.
Penning TD
Curr Opin Drug Discov Devel; 2010 Sep; 13(5):577-86. PubMed ID: 20812149
[TBL] [Abstract][Full Text] [Related]
8. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors.
Iwashita A; Hattori K; Yamamoto H; Ishida J; Kido Y; Kamijo K; Murano K; Miyake H; Kinoshita T; Warizaya M; Ohkubo M; Matsuoka N; Mutoh S
FEBS Lett; 2005 Feb; 579(6):1389-93. PubMed ID: 15733846
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents.
Bryant HE; Helleday T
Biochem Soc Trans; 2004 Dec; 32(Pt 6):959-61. PubMed ID: 15506935
[TBL] [Abstract][Full Text] [Related]
10. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
Putt KS; Hergenrother PJ
Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
[TBL] [Abstract][Full Text] [Related]
11. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Ratnam K; Low JA
Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
[TBL] [Abstract][Full Text] [Related]
12. Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase.
Hattori K; Kido Y; Yamamoto H; Ishida J; Iwashita A; Mihara K
Bioorg Med Chem Lett; 2007 Oct; 17(20):5577-81. PubMed ID: 17804225
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
Nguewa PA; Fuertes MA; Valladares B; Alonso C; Pérez JM
Prog Biophys Mol Biol; 2005 May; 88(1):143-72. PubMed ID: 15561303
[TBL] [Abstract][Full Text] [Related]
14. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling.
Ruf A; de Murcia G; Schulz GE
Biochemistry; 1998 Mar; 37(11):3893-900. PubMed ID: 9521710
[TBL] [Abstract][Full Text] [Related]
15. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Menear KA; Adcock C; Boulter R; Cockcroft XL; Copsey L; Cranston A; Dillon KJ; Drzewiecki J; Garman S; Gomez S; Javaid H; Kerrigan F; Knights C; Lau A; Loh VM; Matthews IT; Moore S; O'Connor MJ; Smith GC; Martin NM
J Med Chem; 2008 Oct; 51(20):6581-91. PubMed ID: 18800822
[TBL] [Abstract][Full Text] [Related]
16. Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Gandhi VB; Luo Y; Liu X; Shi Y; Klinghofer V; Johnson EF; Park C; Giranda VL; Penning TD; Zhu GD
Bioorg Med Chem Lett; 2010 Feb; 20(3):1023-6. PubMed ID: 20045315
[TBL] [Abstract][Full Text] [Related]
17. Effect of simulated microgravity conditions on poly(ADP-ribose) polymerase activity in primary cultures of adult rat hepatocytes.
Cesarone CF; Pippia P; Demori I; Scarabelli L; Fugassa E
J Gravit Physiol; 2001 Jul; 8(1):P127-8. PubMed ID: 12650200
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
Jagtap P; Szabó C
Nat Rev Drug Discov; 2005 May; 4(5):421-40. PubMed ID: 15864271
[TBL] [Abstract][Full Text] [Related]
19. The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis.
Ruf A; Rolli V; de Murcia G; Schulz GE
J Mol Biol; 1998 Apr; 278(1):57-65. PubMed ID: 9571033
[TBL] [Abstract][Full Text] [Related]
20. Toward specific functions of poly(ADP-ribose) polymerase-2.
Yélamos J; Schreiber V; Dantzer F
Trends Mol Med; 2008 Apr; 14(4):169-78. PubMed ID: 18353725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
